Market closed

Kura Oncology/$KURA

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Kura Oncology

Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.

Ticker

$KURA
Sector
Health Care
Trading on
NASDAQ

Industry

Biotechnology
Headquarters
San Diego, United States

Employees

142
Website
kuraoncology.com

Kura Oncology Metrics

BasicAdvanced
$565M
-
-$2.36
0.86
-

$565M

0.86

$24.17

$6.98

1.7M

11.473

11.394

3.12

3.924

-135.09%

-28.54%

-46.28%

1.33

1.33

-3.591

16.79%

7.05%

What the Analysts think about Kura Oncology

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Kura Oncology stock.

Kura Oncology Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Kura Oncology Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

Kura Oncology News

AllArticlesVideos
Kura Oncology Announces Senior Executive Promotions

Kura Oncology Announces Senior Executive Promotions

GlobeNewsWire·1 week ago
Kura Oncology Presents Deep Value At Today's Prices (Rating Upgrade)

Kura Oncology Presents Deep Value At Today's Prices (Rating Upgrade)

Seeking Alpha·4 weeks ago
Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib at American Society of Hematology Annual Meeting

Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib at American Society of Hematology Annual Meeting

GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $KURA

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Kura Oncology stock?

Kura Oncology (KURA) has a market cap of $565M as of January 15, 2025.

What is the P/E ratio for Kura Oncology stock?

The price to earnings (P/E) ratio for Kura Oncology (KURA) stock is 0 as of January 15, 2025.

Does Kura Oncology stock pay dividends?

No, Kura Oncology (KURA) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Kura Oncology dividend payment date?

Kura Oncology (KURA) stock does not pay dividends to its shareholders.

What is the beta indicator for Kura Oncology?

Kura Oncology (KURA) has a beta rating of 0.86. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.